osimertinib
astrazeneca
['lung', 'osimertinib']
os benefit for adjuvant osimertinib vs placebo in locally advanced (stage ib-iiia) egfrm non-small cell lung cancer. hr of 0.49 #asco2023 
29. MD. PhD student. Medical Oncologist. ES 🇪🇸| EN 🇬🇧| FR 🇫🇷| ZH 🇨🇳| 救死扶傷 ⚕️Avid traveller! ✈️🌏